Physician profile
Leor Matalon
NPI 1114952876
$11,586.91
in general payments reported to CMS, 2019-2025
21 companies · $2,174 in 2025
The $2,174 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,533 · 2020: $623 · 2021: $553 · 2022: $1,514 · 2023: $2,814 · 2024: $2,376 · 2025: $2,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,221 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,221.19 |
| Education | $143.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,265.24 | 2022-2025 | Caplyta |
| Abbvie INC. | $1,799.82 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $1,269.03 | 2019-2022 | |
| Alkermes, INC. | $1,175.66 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $863.64 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $700.98 | 2019-2024 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $586.05 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $491.17 | 2019-2024 | Ingrezza |
| Tris Pharma INC | $432.38 | 2022-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $410.73 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $318.82 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $269.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $246.36 | 2025 | Cobenfy |
| Allergan, INC. | $226.72 | 2020 | |
| Idorsia Pharmaceuticals US INC | $219.46 | 2022-2023 | Quviviq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $131.54 | 2019-2024 | Trintellix |
| Corium, LLC | $70.04 | 2023 | Azstarys |
| Neos Therapeutics, LP | $42.95 | 2025 | Adzenys Xr-Odt |
| Lundbeck LLC | $27.69 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $19.92 | 2021 | |
| Collegium Pharmaceutical, INC. | $18.98 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leor Matalon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.